## Simon L Parsons

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11999484/publications.pdf

Version: 2024-02-01

840776 1058476 2,086 15 11 14 citations h-index g-index papers 15 15 15 2470 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut, 2014, 63, 7-42.	12.1	1,116
2	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. International Journal of Cancer, 2010, 127, 2209-2221.	5.1	464
3	Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology, 2009, 54, 699-712.	2.9	164
4	Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. European Journal of Surgical Oncology, 1997, 23, 526-531.	1.0	92
5	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology, 2018, 155, 1720-1728.e4.	1.3	67
6	Novel staining pattern of p53 in Barrett's dysplasia – the absent pattern. Histopathology, 2010, 57, 933-935.	2.9	47
7	3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 753-763.	4.1	30
8	The role of adjuvant platinumâ€based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. Journal of Surgical Oncology, 2017, 115, 821-829.	1.7	30
9	The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study. Clinical Cancer Research, 2014, 20, 3348-3357.	7.0	17
10	Development of a telehealth monitoring service after colorectal surgery: A feasibility study. World Journal of Gastrointestinal Surgery, 2017, 9, 193-199.	1.5	16
11	A systematic review of patient reported outcome measures (PROMs) and quality of life reporting in patients undergoing laparoscopic cholecystectomy. Hepatobiliary Surgery and Nutrition, 2019, 8, 228-245.	1.5	14
12	Individual patient oesophageal cancer 3D models for tailored treatment. Oncotarget, 2017, 8, 24224-24236.	1.8	12
13	Oesophago-Gastric Cancer. , 2012, , 221-244.		9
14	Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center. Journal of Gastrointestinal Cancer, 2018, 49, 85-92.	1.3	5
15	The management and long-term outcomes of endoscopic and surgical treatment of early esophageal adenocarcinoma. Ecological Management and Restoration, 2020, 33, .	0.4	3